Stockreport

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) [Seeking Alpha]

EyePoint Pharmaceuticals, Inc.  (EYPT) 
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF Summary EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequen [Read more]